Literature DB >> 20347281

Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?

S G Coulson1, V S Kumar, I M Manifold, M Q Hatton, S Ramakrishnan, K S Dunn, O P Purohit, C Bridgewater, R E Coleman.   

Abstract

This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability. Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20347281     DOI： 10.1016/j.clon.2010.02.011

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  7 in total

1.  Genomic testing and therapies for breast cancer in clinical practice.

Authors:  Jennifer S Haas; Kathryn A Phillips; Su-Ying Liang; Michael J Hassett; Carol Keohane; Elena B Elkin; Joanne Armstrong; Michele Toscano
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.

Authors:  Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; Nicole Leoce; Christine B Ambrosone; Dana H Bovbjerg; Jeanne S Mandelblatt; Dawn L Hershman
Journal:  Breast Cancer       Date:  2014-06-06       Impact factor: 4.239

3.  HER2 evaluation and its impact on breast cancer treatment decisions.

Authors:  K A B Goddard; S Weinmann; K Richert-Boe; C Chen; J Bulkley; C Wax
Journal:  Public Health Genomics       Date:  2011-05-03       Impact factor: 2.000

4.  A pharmacogenomic method for individualized prediction of drug sensitivity.

Authors:  Adam L Cohen; Raffaella Soldi; Haiyu Zhang; Adam M Gustafson; Ryan Wilcox; Bryan E Welm; Jeffrey T Chang; Evan Johnson; Avrum Spira; Stefanie S Jeffrey; Andrea H Bild
Journal:  Mol Syst Biol       Date:  2011-07-19       Impact factor: 11.429

5.  Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?

Authors:  R M Webster; J Abraham; N Palaniappan; A Caley; B Jasani; P Barrett-Lee
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

6.  Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study.

Authors:  Ling Xu; Yinhua Liu; Zhimin Fan; Zefei Jiang; Yunjiang Liu; Rui Ling; Jianguo Zhang; Zhigang Yu; Feng Jin; Chuan Wang; Shude Cui; Shu Wang; Dahua Mao; Bing Han; Tao Wang; Geng Zhang; Ting Wang; Baoliang Guo; Lixiang Yu; Yingying Xu; Fangmeng Fu; Zhenzhen Liu; Siyuan Wang; Ke Luo; Qian Xiang; Zhuo Zhang; Qianxin Liu; Bin Zhou; Zhaorui Liu; Chao Ma; Weiwei Tong; Jie Mao; Xuening Duan; Yimin Cui
Journal:  Front Oncol       Date:  2021-03-16       Impact factor: 6.244

7.  The use of trastuzumab affected by health insurance policy in Jiangsu Province of China.

Authors:  Yiqin Xia; Mingjie Zheng; Xiang Zhan; Ying Liu; Susheng Cao; Qing Shao; Dong Meng; Liyan Jin; Lingyun Xu; Tongbo Yi; Hui Xie; Shui Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.